3 stories
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.